Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...
A new report compared the blood immune repertoires of patients with chronic lymphocytic leukemia (CLL) who received chemoimmunotherapy and those who received ibrutinib. A new comparison of ...
Children and adults with relapsed/refractory KMT2A rearranged acute leukemia may obtain promising response rates with revumenib, a novel targeted therapy. Patients with relapsed or refractory KMT2A ...
After establishing Venclexta as a treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), AbbVie and Roche were hoping to demonstrate the med's promise in a subset of ...
Please provide your email address to receive an email when new articles are posted on . Revumenib conferred complete remission or complete remission with partial hematologic recovery in nearly ...
B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback